DealsJul 8, 2026, 08:02 AM
Alkermes, Amneal Terminate VIVITROL® Generic Supply Deal
AI Summary
Alkermes plc and Amneal Pharmaceuticals LLC have terminated their Authorized Generic Product Supply Agreement, originally established on September 9, 2025. The agreement granted Amneal rights to distribute an authorized generic version of VIVITROL® in the U.S. The termination occurred on July 6, 2026, after Amneal failed to meet certain terms and subsequently decided not to order any product batches. Alkermes did not incur any penalties, and both parties have released all claims against each other.
Key Highlights
- Alkermes and Amneal Pharmaceuticals terminated their Authorized Generic Product Supply Agreement on July 6, 2026.
- The original agreement, signed September 9, 2025, concerned an authorized generic of VIVITROL®.
- Amneal was granted rights to distribute and sell the generic in the U.S. for a one-year term.
- Alkermes Pharma Ireland Limited (APIL) was to supply the product at a premium to manufacturing cost.
- Termination followed Amneal not meeting certain terms and deciding not to order any batches.
- Alkermes did not incur any penalties in connection with the termination.
- Both parties released all claims against each other related to the agreement.
Price Impact
More from ALKS